Allergan's ubrogepant meets in Phase III for acute migraine

Allergan plc (NYSE:AGN) said ubrogepant (MK-1602) met the co-primary endpoints in the Phase III ACHIEVE I trial for the acute treatment of migraine. The company expects data this half from the

Read the full 313 word article

User Sign In